Business Context and Reporting Period
Collegium Pharmaceutical, Inc. (COLL) filed a Form 8-K on April 26, 2024, reporting the entry into a material definitive agreement. The company is incorporated in Virginia and trades on the NASDAQ Global Select Market.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the terms of a new commercial agreement.
Material Changes and Agreement Details
On April 26, 2024, Collegium entered into an Authorized Generic (AG) Agreement with Hikma Pharmaceuticals USA Inc. Key terms include:
- Products: Exclusive rights granted to Hikma for authorized generic versions of Collegium's Nucynta IR and Nucynta ER products in the United States.
- Launch Timing: Hikma agreed to launch the authorized generics 30 days prior to the loss of exclusivity for each product, or earlier under specific circumstances.
- Profit Sharing: Hikma will pay Collegium a percentage of Net Profits on sales. The initial profit share for Collegium begins in the mid-80% range and declines based on the number of third-party generic equivalents sold.
- Supply Chain: Collegium will supply Hikma with the Nucynta AG Products at fully burdened manufacturing cost. Hikma is restricted from purchasing these products from other sources during the term.
- Exclusivity: Hikma is prohibited from marketing any other generic equivalent of Nucynta IR or ER while marketing the authorized generics.
- Term: The agreement has an initial five-year term with automatic one-year renewals unless terminated by either party.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance or management commentary on future performance. The agreement includes termination provisions for uncured material breach or bankruptcy/insolvency events. Additionally, if Hikma elects to launch its own generic equivalent and terminate the AG Agreement, it must provide one year's notice, which can only be given on or after the first anniversary of the first product launch.
Investor Verification Checklist
- Verify the specific definition of "Net Profits" in the full AG Agreement to understand the revenue calculation basis.
- Monitor the exact dates of loss of exclusivity for Nucynta IR and Nucynta ER to confirm the 30-day launch window.
- Review the full agreement (to be filed as an exhibit to the Q2 2024 Form 10-Q) for details on the declining profit share schedule.
- Assess the impact of third-party generic entry on the projected profit share percentage.